Attendees: A. Barrow, W. Baxter, S. Chien, B. Craig, D. Cuplin, I. Famili, D. Gough, E. Hickman, M. Konno, I. Lian, A. Paau, J. Penhune, L. Phillips, M.Sekins, S. Stokels, I. Tyus

Approval of Minutes from 05/04/00 meeting: Approved as submitted.

Presentation on Edwards Lifesciences, Inc. by Mr. Mark Konno: Edwards Lifesciences is a global leader in providing a comprehensive line of products and services to treat late-stage cardiovascular disease. Edwards is the worldwide leader in the design, development, manufacture and marketing of tissue heart valves and heart valve repair products. Many products manufactured by Edwards occupy leading positions around the world, and the company's engineers and scientists work closely with leading clinicians worldwide, which has allowed Edwards to develop and commercialize new products and to pioneer new treatment techniques. Edwards' sales are categorized in four main product areas: cardiac surgery, critical care, vascular, and perfusion products and services. Edwards is headquartered in Irvine, California, and supplies its products and services to customers in more than 80 countries, both through direct sales and distributor relationships. Cardiovascular disease is the No. 1 cause of death in the world, and is among the top three diseases in terms of healthcare spending in nearly every country in the world. Around the world, more than $180 billion is spent each year for the treatment of cardiovascular disease. Cardiovascular disease is both progressive and pervasive -- progressive, in that it tends to worsen over time, and pervasive because it often affects an individual's entire circulatory system. In its later stages, surgery frequently becomes the preferred treatment option. In 1998, more than 1 million open heart surgeries were performed worldwide; of these, approximately 64 percent were coronary artery bypass graft (CABG) procedures, approximately 24 percent were heart valve replacement or repair procedures, and approximately 12 percent were related to the repair of congenital heart defects. Patients undergoing surgical treatment for cardiovascular disease are likely to encounter a variety of Edwards Lifesciences' products and services. For example, an individual with a heart valve disorder may have a faulty valve re-shaped and repaired with a Cosgrove-Edwards annuloplasty ring, or the surgeon may elect to remove the valve altogether and replace it with a Carpentier-Edwards PERIMOUNT handcrafted bioprosthetic heart valve, which can be made of bovine or porcine tissue. If a patient undergoes other types of open-heart surgery, such as a CABG procedure, the functions of their heart and lungs may be managed through the use of disposable products and equipment offered in Edwards' Bentley or Research Medical product lines. The perfusion procedure may be performed by a clinical perfusionist from Edwards' Lifesciences Cardiovascular Resources, the largest organization of contract cardiovascular specialists in the world. If the circulatory problems are in the limbs rather than in the heart, the patient's procedure may involve some of Edwards' Fogarty vascular products, which include various types of balloon-tipped catheters that are used to remove blood clots. Finally, virtually all high-risk patients in the operating room or cardiac-care unit are candidates for having their cardiac function monitored by Edwards' Swan-Ganz line of critical care products. Edwards Lifesciences' comprehensive line of cardiovascular products and services are categorized into four main areas: Cardiac Surgery, encompassing heart valve implantables, and cannulae and cardioplegia, which are used to access and support the heart during open-hospital surgery; Critical Care, featuring cardiac monitoring systems and disposables used to evaluate cardiac output and measure blood pressure; Vascular, which includes products used in peripheral vascular surgery, surgical accessories, implantable grafts, and endovascular graft systems for treating aortic aneurysms; and Perfusion Products and Services, comprised of oxygenators and related disposables used during cardiopulmonary bypass, cardiopulmonary bypass hardware and perfusion services.

Groundbreaking Follow-up:
Dr. Chien thanked all of those who were able to attend the August groundbreaking of the Powell-Focht Bioengineering Hall. Mr. Duane Roth, CEO of Alliance Pharmaceutical, and Dr. Wendy Baldwin, Deputy Director for Extramural Research and Chair of the Bioengineering Consortium (BECON) at the National Institutes of Health gave superb presentations on the perspectives of bioengineering in industry and at the NIH. The groundbreaking helped generated great enthusiasm in the Department and in WIBE.

Conference on Glucose Monitoring and Control:
Dr. David Gough announced the first ever Conference on Glucose Monitoring and Control, which will be held this February 15-17, 2001 at the Radisson Hotel La Jolla. The conference is sponsored in part by the newly approved Project on Glucose Monitoring and Control established as part of the Whitaker Institute of Biomedical Engineering. The conference will be a gathering of top researchers in the field to discuss the new sensing technologies, to review approaches for validation of sensor system performance, and to begin the discussion about how information from new sensing technologies can best be used to facilitate improved blood glucose control. There will be an opportunity for presentations, informal discussions, and poster presentations.

Update on Current Events:
Iman Famili introduced the new Bioengineering Student Group representatives, Ian Lian and Shula Stokels. Ian and Shula will be taking over the duties of Iman and Ilka as the graduate student representatives at the Industrial Advisory Board meetings.

Shula Stolkes gave a brief report on this year's Graduate Students Breakfast with Industry, which is planned for November 3, 2000. This years keynote speaker is Mr. Paul Citron, Vice President of Science and Technology at Medtronic, Inc. The Breakfast will be held in the UCSD Faculty Club from 7:30am - 9:00am. Shula also notified the board of the date of the Graduate Student Research Symposium. This year's Symposium is planned for March 10, 2001 on the UCSD campus. Formal invitation to the event will be mailed out in early February.

Elizabeth Hickman introduced Ms. Imani Tyus. Ms. Tyus is the new Bioengineering Student Internship Coordinator. Ms. Tyus will coordinate both the undergraduate and graduate internship programs. Elizabeth also gave a report on the upcoming Meet the Researchers Series, cosponsored by the WIBE and UCSD CONNECT. The first meeting of the series will be November 10, 2000, with Dr. John Dobak, President and CEO of INNERCOOL therapies, and Dr. Juan Lasheras, Chair of the Department of Mechanical and Aerospace Engineering. Following meetings of the series will be on December 15, 2000, with Dr. Bernhard Palsson, Professor of Bioengineering, and Dr. Christophe Schilling, Chief Technology Officer of Genomatica, and January 26, 2001, with Dr. David Gough, Chair of the Department of Bioengineering, and Dr. Joseph Lucisano, President and CEO of Glysens, Inc. All meetings are held at the UCSD Faculty Club from 7:30am - 9:00am.

The next Industrial Advisory Board Meeting will be February 22, 2001 from 7:30a.m. - 9:00a.m.

Respectfully submitted: Elizabeth Hickman